Co-expression of HER2/EGFRvIII/CD44 and Claudin 18.2/CD109 as Novel Prognostic Indicators in Stomach Adenocarcinoma.

ABSTRACT:

Background

The heterogenous expression of human epidermal growth factor receptor (HER) family members may contribute to poor response to current therapies with HER inhibitors in cancer. This study aimed to explore the co-expression and prognostic significance of HER family members with epidermal growth factor receptor variant III (EGFRvIII), cluster of differentiation 44 (CD44), cluster of differentiation 109 (CD109), and claudin 18.2 (CLDN18.2) in patients with stomach cancer.

Methods

The relative expression and prognostic significance of these biomarkers at different cut-off values were determined in 78 patients with stomach adenocarcinoma by immunohistochemistry.

Results

Of the 78 cases, positive tumor staining was present for wild-type EGFR (13%), HER2 (82%), HER3

SUBMITTER: Al Janaby T 

PROVIDER: S-EPMC12185126 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature